CD40 and neoplasm: Using spatial transcriptomics and single cell sequencing of MC38 tumor cells in mice treated with agonist anti-CD40 antibody therapy, it was demonstrated that heme-driven NRF2 activation in macrophages drives metabolic reprogramming towards immunosuppressive tumor associated macrophages (TAMs) [19].